Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 7Genitourinary 6Myeloid 5Thoracic 4Head & Neck 3Gastrointestinal 2Breast 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Endocrine 1Dermatologic 1CNS 1

Conditions

Skin Neoplasms 1Carotid Intimal Medial Thickness 1 1Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42Specimen Handling 42atezolizumab 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pioglitazone × Dermatologic × Clear all
NCT02347813 2020-06-23

Preventing Squamous Cell Skin Cancer

University of Rochester

Phase 2 Completed
12 enrolled 10 charts
Dermatologic

Carotid Intimal Medial Thickness 1, Carcinoma, Squamous Cell, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡